Endothelial eNAMPT drives EndMT and preclinical PH: rescue by an eNAMPT-neutralizing mAb

Pharmacologic interventions to halt/reverse the vascular remodeling and right ventricular dysfunction in pulmonary arterial hypertension (PAH) remains an unmet need. We previously demonstrated extracellular nicotinamide phosphoribosyltransferase (eNAMPT) as a DAMP (damage-associated molecular patter...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Mohamed Ahmed, Nahla Zaghloul, Prisca Zimmerman, Nancy G. Casanova, Xiaoguang Sun, Jin H. Song, Vivian Reyes Hernon, Saad Sammani, Franz Rischard, Olga Rafikova, Ruslan Rafikov, Ayako Makino, Carrie L. Kempf, Sara M. Camp, Jian Wang, Ankit A. Desai, Yves Lussier, Jason X.-J. Yuan, Joe G.N. Garcia
Format:	article
Langue:	EN
Publié:	SAGE Publishing 2021
Sujets:	Diseases of the circulatory (Cardiovascular) system RC666-701 Diseases of the respiratory system RC705-779
Accès en ligne:	https://doaj.org/article/01ea69ffb6ab44d592257d77dde80f26
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Endothelial eNAMPT drives EndMT and preclinical PH: rescue by an eNAMPT-neutralizing mAb

Documents similaires